Prosecution Insights
Last updated: November 20, 2026

Kristin Ann Vajda, USPTO Patent Examiner

Listed by the USPTO as VAJDA, KRISTIN ANN

Tech Center 1600 • Art Units: 1622 1624 1626

This examiner grants 84% of resolved cases

Analysis

VAJDA, KRISTIN ANN handles cases in Tech Center 1600 and Art Unit 1622. The profile records 1633 resolved cases and an 83.8% allowance rate. The median time to allowance is 658 days, giving applicants a comparatively direct timing reference for planning prosecution milestones within this examiner's record.

The interview lift is 11.2%, suggesting that interviews have a limited measured association with allowance outcomes here. The listed companies are Pfizer Inc., Samsung Display Co., Ltd., and The Regents of the University of California. NIXON & VANDERHYE, PC, ALSTON & BIRD LLP, and ARENTFOX SCHIFF LLP are the listed firms. Those recurring participants can help counsel identify relevant drafting and response experience.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Performance Statistics

83.8%
Allow Rate
+23.8% vs TC avg
1,672
Total Applications
+11.2%
Interview Lift
658
Avg Prosecution Days
Based on 1633 resolved cases, 2023–2026

Rejection Statute Breakdown

4.2%
§101 Eligibility
26.6%
§102 Novelty
12.1%
§103 Obviousness
34.2%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18702299 ORGANIC MOLECULES FOR OPTOELECTRONIC DEVICES Non-Final OA Samsung Display Co., Ltd.
18287646 THERAPY FOR ALCOHOL-RELATED LIVER DISEASE Non-Final OA THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
18322819 DONOR-ACCEPTOR-DONOR TYPE MATERIALS FOR OPTOELECTRONIC APPLICATIONS Non-Final OA The Regents of the University of Michigan
17282319 Transcription Factor BRN2 Inhibitory Compounds as Therapeutics and Methods for Their Use Final Rejection The University of British Columbia
18700945 COMPOSITION USED TO PREVENT OR SUPPRESS REFEEDING SYNDROME Non-Final OA OTSUKA PHARMACEUTICAL FACTORY, INC.
18687441 TREATMENT OF NEURODEGENERATIVE DISEASES WITH HDAC INHIBITORS Non-Final OA CASE WESTERN RESERVE UNIVERSITY
18263772 NOVEL COMPOUND AS PROTEIN KINASE INHIBITORS Non-Final OA LG CHEM, LTD.
18701027 IMPROVED SELECTIVE JAK2 INHIBITORS AND METHODS OF USE Non-Final OA Yale University
18275287 CULLIN-RING E3 UBIQUITIN LIGASE 4 INHIBITOR COMPOUNDS AND METHODS OF THEIR USE Final Rejection ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
18799659 MODULATORS OF MYOCYTE LIPID ACCUMULATION AND INSULIN RESISTANCE AND METHODS OF USE THEREOF Non-Final OA THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Who Appears Before This Examiner

Top companies before this examiner

Law firms appearing most often

Frequently Asked Questions

What is examiner Kristin Ann Vajda's allowance rate?

83.8% of resolved applications examined by Kristin Ann Vajda were allowed (1,633 resolved cases), compared with 60.5% across Art Unit 1622 over the last five years.

Does an interview help with examiner Kristin Ann Vajda?

This examiner's interview lift is +11.2 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.

How long does examiner Kristin Ann Vajda take to allow a patent?

Applications allowed by Kristin Ann Vajda took 658 days on average from filing to allowance.

Which art unit does examiner Kristin Ann Vajda work in?

Kristin Ann Vajda examines applications in Art Unit 1622 in Tech Center 1600 (Biotechnology & Pharmaceuticals).

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month